Literature DB >> 16254305

Orphan drugs and the NHS: should we value rarity?

Christopher McCabe1, Karl Claxton, Aki Tsuchiya.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  2005        PMID： 16254305      PMCID： PMC1273462          DOI： 10.1136/bmj.331.7523.1016

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Theories of justice and their implications for priority setting in health care.

Authors:  J A Olsen
Journal:  J Health Econ       Date:  1997-12       Impact factor: 3.883

2.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

Authors:  Karl Claxton; Mark Sculpher; Michael Drummond
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

3.  Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue.

Authors:  D C Hadorn
Journal:  JAMA       Date:  1991-05-01       Impact factor: 56.272

4.  QALYfying the value of life.

Authors:  J Harris
Journal:  J Med Ethics       Date:  1987-09       Impact factor: 2.903

Review 5.  The rule of rescue.

Authors:  John McKie; Jeff Richardson
Journal:  Soc Sci Med       Date:  2003-06       Impact factor: 4.634
  5 in total
  50 in total

1.  Listening for prescriptions: a national consultation on pharmaceutical policy issues.

Authors:  Steve Morgan; Colleen M Cunningham
Journal:  Healthc Policy       Date:  2010-11

2.  Orphan drugs and the NHS: consider whom drug regulation is designed to protect.

Authors:  Tom Marshall
Journal:  BMJ       Date:  2005-11-12

3.  Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.

Authors:  Mark Sheehan
Journal:  BMJ       Date:  2005-11-12

Review 4.  Commissioning for rare diseases: view from the frontline.

Authors:  Amanda Burls; Daphne Austin; David Moore
Journal:  BMJ       Date:  2005-10-29

5.  Rationing of drugs for rare diseases.

Authors:  Dyfrig Hughes
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

7.  Rare diseases and orphan drugs.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

8.  Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects.

Authors:  Arna S Desser; Jan Abel Olsen; Sverre Grepperud
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

9.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

10.  No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.

Authors:  Pieter Stolk; Harald E Heemstra; Hubert G M Leufkens; Brigitte Bloechl-Daum; Eibert R Heerdink
Journal:  Orphanet J Rare Dis       Date:  2009-12-14       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.